GHRP-2, Ipamorelin (Blend)

🧬 INTRODUCTION: The Dual GHRP Research Platform

Within the family of Growth Hormone-Releasing Peptides (GHRPs) , each analog possesses a distinct pharmacological signature—differences in potency, receptor binding kinetics, downstream signaling bias, and off-target endocrine effects that render them anything but interchangeable . The GHRP-2 and Ipamorelin Blend unites two of the most widely studied GHSR-1a agonists in a single formulation, providing researchers with a powerful tool for comparative pharmacology, pathway dissection, and synergistic GH pulse modeling .

GHRP-2 (Pralmorelin, KP-102) represents the high-potency arm of this blend. A synthetic hexapeptide with strategic D-amino acid incorporation, GHRP-2 delivers maximal GH pulse amplitude, significant somatostatin antagonism, and measurable orexigenic signaling via NPY/AgRP neuron activation .

Ipamorelin represents the selective, sustained arm. A pentapeptide developed by Novo Nordisk, Ipamorelin is distinguished by its exceptional receptor selectivity, producing robust GH release with minimal ACTH, prolactin, or cortisol elevation and negligible appetite stimulation .

When combined, these two GHRPs do not simply produce additive GH release—they enable researchers to:

• Compare biased agonism profiles at the same GHSR-1a receptor
• Model the full spectrum of ghrelinergic signaling, from appetite to metabolic partitioning
• Investigate receptor desensitization kinetics of fast-acting vs. sustained agonists
• Dissect GHSR-1a signal transduction pathways (Gαq/IP₃/PKC/Ca²⁺ vs. potential Gαi/o or β-arrestin recruitment)

At Buy Peptides Online USA, we supply this dual GHRP blend as a high-purity, GMP-manufactured research reagent. Each constituent undergoes independent High Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) verification prior to precision blending—the only scientifically defensible standard for heterogeneous peptide formulations.

✅ WHAT IS THE GHRP-2, IPAMORELIN BLEND?

This blend unites two mechanistically distinct GHSR-1a agonists into a single, pre-formulated research tool for comparative and integrative GHRP research.

🔹 Component Breakdown & Mechanistic Rationale

🔬 GHRP-2 (Pralmorelin; KP-102)
GHRP-2 is a synthetic hexapeptide developed through structure-activity optimization of earlier GHRP compounds. Its strategic incorporation of D-amino acids (D-Ala¹, D-2-Nal², D-Phe⁵) confers significant proteolytic resistance, extending its bioactive half-life and enhancing oral/nasal bioavailability compared to all-L peptides .

Key Mechanistic Attributes:

• Potent GH Pulse Amplitude: GHRP-2 is significantly more potent than GHRP-6 and produces a sharper GH peak with rapid onset (~15 min) .
• Somatostatin Antagonism: Suppresses somatostatin receptor subtype 1 and 2 (sst-1, sst-2) mRNA expression, reducing sensitivity to the endogenous GH brake .
• Orexigenic Effect: Significantly stimulates appetite via NPY/AgRP neuron activation—a distinguishing feature from Ipamorelin .
• Cortisol/PRL Profile: Produces modest, dose-dependent elevations in ACTH, cortisol, and prolactin—generally within physiological range at standard doses (≤100 mcg) .
• Anti-Inflammatory Activity: Suppresses TNF-α, IL-6, and NF-κB activation in inflammatory models .

Molecular Formula: C₄₅H₅₅N₉O₆
Molecular Weight: ~817.97 – 818.0 g/mol
CAS Number: 158861-67-7
Sequence: H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂

🔬 Ipamorelin
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) developed by Novo Nordisk. It functions as a highly selective agonist of the growth hormone secretagogue receptor (GHSR-1a) .

Key Mechanistic Attributes:

• Exceptional Selectivity: Demonstrates GH-releasing efficacy comparable to GHRP-6 with minimal ACTH, prolactin, or cortisol elevation—critical for studies where endocrine confounds must be minimized .
• No Orexigenic Effect: Unlike GHRP-2 and GHRP-6, Ipamorelin produces negligible appetite stimulation, making it preferred for metabolic research .
• Sustained Release Profile: Longer half-life (~2 hours) produces a broader GH peak, modeling a different pulse kinetics than GHRP-2 .
• Sleep Architecture: Studies suggest Ipamorelin may enhance deep NREM sleep via GHRHergic pathway activation .
• Stability: Resistant to enzymatic degradation due to Aib and D-amino acid incorporation; C-terminal amidation.

Molecular Formula: C₃₈H₄₉N₉O₅
Molecular Weight: ~711.9 g/mol
CAS Number: 170851-70-4
Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

The Dual GHRP Synergy:
GHRP-2 provides the high-amplitude, rapid-onset pulse with associated orexigenic signaling. Ipamorelin provides the selective, sustained release with clean endocrine profile. Together, they enable researchers to model the complete spectrum of GHSR-1a activation—from appetite to GH release, from rapid peak to sustained plateau—within a single experimental system .

🧪 PRODUCT SPECIFICATIONS & TECHNICAL DATA SHEET

Critical Quality Note: This blend comprises two GHRPs with different molecular weights and physicochemical properties: GHRP-2 (hexapeptide, 0.8 kDa) and Ipamorelin (pentapeptide, 0.7 kDa). While both are small peptides, their differential hydrophobicity and aromatic residue content (D-2-Nal in both, Trp in GHRP-2) can affect chromatographic resolution. Simultaneous HPLC purity quantitation requires method optimization; we employ component-wise pre-analytical verification as the gold standard .

📊 Comprehensive Peptide Specifications Table

🔬 VERIFIED QUALITY: THE DUAL GHRP VALIDATION PROTOCOL

Analytical Consideration: GHRP-2 and Ipamorelin share structural similarities (both contain D-2-Nal and D-Phe) but differ in length and sequence. Co-injection HPLC is possible with optimized gradients but requires validation to ensure baseline resolution of both peaks. Our approach prioritizes component-wise pre-validation for absolute purity assignment .

Our 4-Tier Verification Protocol:

✅ Tier 1: Component Pre-Analysis. Each raw peptide is individually analyzed via reverse-phase HPLC (C18 column, component-optimized gradients) to confirm ≥98% purity. Identity confirmed via ESI-MS or MALDI-TOF MS against reference standards:

• GHRP-2: ~818 Da [M+H]⁺
• Ipamorelin: ~712 Da [M+H]⁺

✅ Tier 2: Precision Blending. Components are gravimetrically dispensed in ISO 7 (Class 10,000) cleanroom environments using calibrated micro-balances (±0.01 mg accuracy). Blend ratios verified by dual weighing.

✅ Tier 3: Post-Blend Identity Confirmation. The final blend undergoes MS to confirm the presence and correct molecular weight signatures of both peptides.

✅ Tier 4: Endotoxin & Bioburden. LAL chromogenic assay verification of <0.05 EU/mg—essential for sensitive primary cell culture and in vivo applications.

"For dual GHRP blends, component-wise pre-validation with full analytical traceability ensures researchers know exactly what they are working with—critical for studies comparing receptor pharmacology." — Adapted from analytical chemistry protocols for peptide combinations.

🧬 PRIMARY RESEARCH APPLICATIONS & TYPICAL RESEARCH FOCUSES

This dual GHRP blend is designed exclusively for controlled laboratory investigations. Below are the predominant domains of preclinical inquiry:

1. 📈 Comparative GHSR-1a Pharmacology & Biased Agonism

Primary Function/Purpose: Research, Receptor Pharmacology, Signal Transduction
Key Focus: Gαq vs. β-arrestin signaling, receptor binding kinetics, functional selectivity.

• GHRP-2 and Ipamorelin are both full agonists at GHSR-1a, but they may exhibit biased agonism—differential activation of downstream pathways (IP₃/Ca²⁺ vs. MAPK/ERK vs. β-arrestin recruitment) .
• This blend enables head-to-head comparison of two clinically relevant GHRPs within the same experimental system.
• Research Model: GHSR-1a transfected HEK293 cells; intracellular calcium flux assays; IP₁ accumulation HTRF; β-arrestin recruitment assays (Tango, BRET); pERK Western blot.

2. 🧠 Appetite & Energy Homeostasis Research

Primary Function/Purpose: Weight Management, Metabolic Research, Obesity Studies
Key Focus: Orexigenic vs. non-orexigenic GHSR signaling, NPY/AgRP neuron activation.

• GHRP-2 provides significant, measurable orexigenic signaling via NPY/AgRP neuron activation—a positive control for ghrelinergic appetite studies .
• Ipamorelin provides negligible appetite stimulation, serving as a negative control or comparator for dissecting GH-dependent vs. appetite-dependent metabolic effects .
• Research Application: Enables researchers to disentangle the orexigenic and GH-releasing effects of GHSR-1a activation.
• Research Model: DIO rodent models; metabolic cage studies; NPY/AgRP neuron calcium imaging; pair-feeding paradigms; food intake monitoring.

3. 📈 GH Pulse Kinetics & Desensitization Studies

Primary Function/Purpose: Growth Hormone Support, Neuroendocrine Research
Key Focus: Pulse amplitude vs. duration, receptor desensitization, somatostatin antagonism.

• GHRP-2 models maximal pulse amplitude with rapid onset (~15 min peak) and shorter duration .
• Ipamorelin models broader, sustained pulse with slower offset (~2 hr half-life) .
• Combined, they enable investigation of differential receptor desensitization kinetics and GHRP-specific effects on somatostatin receptor expression .
• Research Model: Primary rat pituitary cell culture; serial blood sampling with GH-ELISA; receptor mRNA quantification (qPCR); cAMP/PKC pathway inhibitor studies.

4. 🔬 ACTH, Prolactin & Cortisol Pharmacology

Primary Function/Purpose: Endocrine Research, Pituitary Hormone Interactions
Key Focus: Off-target endocrine effects, dose-response characterization.

• GHRP-2 at saturation dose (100 mcg) produces small, transient increases in prolactin and cortisol—within physiological range but measurable .
• Ipamorelin produces minimal to no ACTH/prolactin/cortisol elevation .
• This blend enables direct comparison of the two GHRPs' effects on the HPA axis and lactotrophs.
• Research Model: Primary pituitary corticotroph/lactotroph culture; ACTH, prolactin, cortisol ELISA; CRH stimulation tests.

5. 🧪 Anti-Inflammatory & Immunomodulatory Research

Primary Function/Purpose: Immune Support, Anti-Inflammatory, Cytokine Research
Key Focus: NF-κB suppression, cytokine modulation.

• GHRP-2 has documented anti-inflammatory activity: suppresses TNF-α and IL-6, inhibits NF-κB activation, reduces superoxide anions .
• Ipamorelin's anti-inflammatory profile is less characterized, enabling comparative studies of GHRP-specific immunomodulation.
• Research Model: LPS-stimulated macrophages; acute lung injury rodent models; ELISA cytokine arrays; NF-κB luciferase reporters.

6. 🧪 Gastrointestinal Motility Research

Primary Function/Purpose: Gastrointestinal Research
Key Focus: Gastric contractility, ghrelin receptor effects.

• GHRP-2 inhibits gastrointestinal contractility in conscious animal models .
• Ipamorelin's GI effects are less studied, enabling comparative investigation.
• Research Model: Conscious dog GI motility recording; isolated gastric smooth muscle strips.

❄️ HANDLING, STORAGE & RECONSTITUTION PROTOCOL

Critical Note: Both GHRP-2 and Ipamorelin are stable when lyophilized and stored frozen. Reconstituted solutions should not be frozen and should be used within 28 days .

🧊 Storage Integrity Protocol

💧 Standardized Reconstitution Protocol (4mg Total Mass)

Based on validated laboratory protocols for 2mg GHRP-2 + 2mg Ipamorelin :

1. Equilibration: Allow vial to reach room temperature in a desiccated environment (15-20 minutes) to prevent moisture condensation.
2. Solvent Selection: Use Bacteriostatic Water (0.9% Benzyl Alcohol) for multi-use studies.
3. Volume Calculation: Inject 2.0 mL of solvent.
   • Final Concentration: 2.0 mg/mL total peptide.
   • Component Concentrations: 1.0 mg/mL each (GHRP-2 and Ipamorelin).
4. Technique: Insert syringe at 45° angle. Direct fluid slowly against the inner vial wall. Do NOT shake. Gently swirl or roll for 60 seconds.
5. Visual Inspection: Solution should be clear and colorless. Discard if particulate matter present.

📊 Syringe Measurement Reference (U-100 Insulin Syringe)

At 2.0 mL reconstitution volume (1.0 mg/mL concentration per component) :

⏱️ Research Dosing Frequency Guidance

For chronic studies, the optimal frequency depends on which GHRP's kinetics are being modeled:

• For GHRP-2-dominant effects (sharp pulses): 3x daily (e.g., 0800, 1400, 2000)
• For Ipamorelin-dominant effects (sustained elevation): 2-3x daily possible due to longer half-life
• Minimum 3-4 hour interval recommended to prevent receptor desensitization .

❓ FREQUENTLY ASKED QUESTIONS (FAQ)

Q: What is the experimental rationale for combining GHRP-2 and Ipamorelin? Aren't they both just GHRPs?

A: This is an excellent question and the key research value of this blend. While both are GHSR-1a agonists, they represent different pharmacological classes:

Research Applications of the Blend:

1. Comparative Pharmacology: Directly compare two GHRPs in the same assay.
2. Signal Dissection: Use their different profiles to dissect which effects are GHSR-1a mediated vs. off-target.
3. Combination Modeling: Investigate whether combining a fast, high-amplitude GHRP with a sustained, selective GHRP produces unique pulse kinetics or receptor regulation patterns.

Q: Does this blend require co-administration with a GHRH analog (e.g., CJC-1295 no DAC)?

A: Not for all studies. This blend can be used alone to study isolated GHSR-1a signaling and the differential effects of two GHRPs. However, for studies modeling maximal physiological GH release (as in somatotropic axis research), it is typically combined with a GHRH analog to achieve GHRH–GHRP synergy. The blend format simply provides the two GHRPs pre-mixed; the GHRH analog (if needed) would be added separately .

Q: What is the saturation dose for each component?

A: For both GHRP-2 and Ipamorelin, the saturation dose is 100 mcg per pulse in most animal and human studies. Doses above this produce diminishing returns in GH release but increasing off-target effects (prolactin/cortisol for GHRP-2) .

Q: Does Ipamorelin reduce the cortisol/prolactin elevation caused by GHRP-2 in this blend?

A: This is an empirical question that can be investigated using this blend. The two peptides act on the same receptor population but may have different signaling biases. Whether co-administration alters the net endocrine profile is a valid research question that this blend enables you to answer .

Q: What is the Aib residue in Ipamorelin?

A: Aib (α-aminoisobutyric acid) is a non-proteinogenic, achiral amino acid. It induces helical conformation and confers exceptional proteolytic stability, contributing to Ipamorelin's longer half-life and receptor selectivity .

Q: What is D-2-Nal and why is it in both peptides?

A: D-2-Naphthylalanine is a non-natural amino acid with a bulky naphthalene side chain. It is critical for high-affinity GHSR-1a binding. The naphthalene ring engages in hydrophobic stacking interactions with aromatic residues in the receptor's transmembrane binding pocket .

Q: Do you provide medical dosage instructions?

A: Absolutely not. As a Research Use Only (RUO) supplier, we strictly prohibit providing medical or veterinary instructions. Determining the appropriate dose, concentration, and administration route for your specific IACUC-approved protocol is the sole responsibility of the qualified Principal Investigator (PI).

🧬 PEPTIDE STRUCTURE & STABILITY INSIGHTS

Strategic D-Amino Acids in GHRP-2:
GHRP-2 contains three D-amino acids (D-Ala¹, D-2-Nal², D-Phe⁵). This confers:

• Resistance to proteolytic cleavage by exopeptidases
• Extended bioactive half-life compared to all-L peptides
• Enhanced receptor binding affinity (D-2-Nal²)

Aib in Ipamorelin: The "Helix Inducer":
Aib (α-aminoisobutyric acid) is an achiral, α,α-disubstituted amino acid that strongly favors helical conformation. This structural rigidity:

• Confers exceptional resistance to proteolysis
• Positions the pharmacophore residues optimally for receptor binding
• Contributes to receptor selectivity and biased agonism potential

Shared D-2-Nal Motif:
Both peptides contain D-2-Nal (GHRP-2 at position 2, Ipamorelin at position 3). This non-natural residue is essential for high-affinity binding to GHSR-1a. The naphthalene ring engages in π-π stacking interactions with Phe²⁸² and Phe²⁹⁹ in the receptor's transmembrane domain .

C-Terminal Amidation (-NH₂):
Both peptides feature C-terminal amidation. This neutralizes the negative charge of the terminal carboxyl group, improving receptor recognition and proteolytic stability by blocking carboxypeptidase cleavage.

Disulfide Bonds: Neither peptide contains disulfide bonds; both are linear and stable under standard handling conditions.

🚀 WHY PURCHASE GHRP-2, IPAMORELIN BLEND FROM BUY PEPTIDES ONLINE USA?

The peptide supply landscape is heterogeneous. We differentiate through analytical transparency and researcher-first logistics.

✅ Component-Verified Purity: Each constituent is tested individually (≥98% HPLC/MS) prior to precision blending—essential for accurate pharmacology studies.
✅ Authentic Sequences: GHRP-2 (CAS 158861-67-7, sequence verified). Ipamorelin (CAS 170851-70-4, sequence verified). No substitutions.
✅ Third-Party Transparency: Independent COA documentation per batch—no proprietary secrecy. Full analytical traceability.
✅ GMP-Ancillary Manufacturing: Produced in ISO 9001-aligned facilities; rigorous environmental monitoring and documentation.
✅ Low Endotoxin: <0.05 EU/mg—suitable for sensitive primary cell culture and in vivo work.
✅ Cold-Chain Packaging: Lyophilized peptides shipped with temperature-indicating desiccants and insulated containers.
✅ Authenticity Guarantee: Full replacement or refund if product fails independent verification of stated specifications.
✅ Secure Crypto Payments: Bitcoin, Ethereum, USDT accepted for discreet, frictionless transactions.
✅ 24/7 Technical Support: Protocol consultation regarding reconstitution, solubility, and handling (RUO context only).
✅ USA-Based Operations: Rapid fulfillment from domestic distribution hubs. Free shipping on orders over $300.
✅ Bulk Availability: Volume discounts for institutional laboratories (contact for custom quotas).

📦 PACKAGING & DELIVERY INTELLIGENCE

• Primary Container: Sterile, crimp-sealed Type I borosilicate glass vial.
• Fill Strength: 4mg total mass (2mg GHRP-2 / 2mg Ipamorelin).
• Protection: Foil pouch with integrated desiccant; anti-static cushioning.
• Discretion: Plain, non-descript outer carton.
• Lead Time: Orders processed within 1-2 business days. USA delivery: 2-5 business days.
• International: Worldwide shipping available, subject to local import/export compliance.

⚖️ LEGAL & COMPLIANCE DISCLAIMER

STRICT RESEARCH USE ONLY (RUO).

• NOT FOR HUMAN OR VETERINARY CONSUMPTION.
• NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.
• NOT FDA APPROVED.

This product is intended solely for in vitro or animal model research by qualified professionals in a controlled laboratory setting. GHRP-2, Ipamorelin, and all growth hormone secretagogues are prohibited substances in competitive sports under WADA regulations. Researchers must ensure compliance with all applicable institutional, local, state, and federal regulations.

All product information, including proposed mechanisms and applications, is derived from peer-reviewed literature and is presented for educational purposes only. It does not constitute medical advice or a claim regarding the treatment or cure of any disease or condition .

By purchasing, the buyer confirms compliance with all applicable regulations and institutional oversight.